Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study.

Paiva, Jose-Artur; Pereira, Jose Manuel; Tabah, Alexis; Mikstacki, Adam; de Carvalho, Frederico Bruzzi; Koulenti, Despoina; Ruckly, Stephane; Cakar, Nahit; Misset, Benoît; Dimopoulos, George; Antonelli, Massimo; Rello, Jordi; Ma, Xiaochun; Tamowicz, Barbara; Timsit, Jean-Francois

doi:10.1186/s13054-016-1229-1

Article (Scientific journals)

Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study.

Paiva, Jose-Artur; Pereira, Jose Manuel; Tabah, Alexis et al.

2016 • In Critical care (London, England), 20, p. 53

Peer reviewed

Permalink
https://hdl.handle.net/2268/245142

DOI
10.1186/s13054-016-1229-1

PubMed
26956367

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

PUBMED 27 - document-2.pdf

Publisher postprint (656.68 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Aged; Antifungal Agents/therapeutic use; Cross Infection/mortality; Female; Fungemia/mortality/pathology; Hospital Mortality/trends; Humans; Iatrogenic Disease; Incidence; Intensive Care Units/statistics & numerical data; Male; Middle Aged; Prospective Studies; Risk Factors

Abstract :

[en] BACKGROUND: To characterize and identify prognostic factors for 28-day mortality among patients with hospital-acquired fungemia (HAF) in the Intensive Care Unit (ICU). METHODS: A sub-analysis of a prospective, multicenter non-representative cohort study conducted in 162 ICUs in 24 countries. RESULTS: Of the 1156 patients with hospital-acquired bloodstream infections (HA-BSI) included in the EUROBACT study, 96 patients had a HAF. Median time to its diagnosis was 20 days (IQR 10.5-30.5) and 9 days (IQR 3-15.5) after hospital and ICU admission, respectively. Median time to positivity of blood culture was longer in fungemia than in bacteremia (48.7 h vs. 38.1 h; p = 0.0004). Candida albicans was the most frequent fungus isolated (57.1%), followed by Candida glabrata (15.3%) and Candida parapsilosis (10.2%). No clear source of HAF was detected in 33.3% of the episodes and it was catheter-related in 21.9% of them. Compared to patients with bacteremia, HAF patients had a higher rate of septic shock (39.6% vs. 21.6%; p = 0.0003) and renal dysfunction (25% vs. 12.4%; p = 0.0023) on admission and a higher rate of renal failure (26% vs. 16.2%; p = 0.0273) at diagnosis. Adequate treatment started within 24 h after blood culture collection was less frequent in HAF patients (22.9% vs. 55.3%; p < 0.001). The 28-day all cause fatality was 40.6%. According to multivariate analysis, only liver failure (OR 14.35; 95% CI 1.17-175.6; p = 0.037), need for mechanical ventilation (OR 8.86; 95% CI 1.2-65.24; p = 0.032) and ICU admission for medical reason (OR 3.87; 95% CI 1.25-11.99; p = 0.020) were independent predictors of 28-day mortality in HAF patients. CONCLUSIONS: Fungi are an important cause of hospital-acquired BSI in the ICU. Patients with HAF present more frequently with septic shock and renal dysfunction on ICU admission and have a higher rate of renal failure at diagnosis. HAF are associated with a significant 28-day mortality rate (40%), but delayed adequate antifungal therapy was not an independent risk factor for death. Liver failure, need for mechanical ventilation and ICU admission for medical reason were the only independent predictors of 28-day mortality.

Disciplines :

Anesthesia & intensive care

Author, co-author :

Paiva, Jose-Artur

Pereira, Jose Manuel

Tabah, Alexis

Mikstacki, Adam

de Carvalho, Frederico Bruzzi

Koulenti, Despoina

Ruckly, Stephane

Cakar, Nahit

Misset, Benoît ; Centre Hospitalier Universitaire de Liège - CHU > Service de Soins Intensifs

Dimopoulos, George

More authors (5 more)

Language :

English

Title :

Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study.

Publication date :

2016

Journal title :

Critical care (London, England)

ISSN :

1364-8535

eISSN :

1466-609X

Volume :

Pages :

Peer reviewed :

Peer reviewed

Available on ORBi :

since 21 February 2020

Statistics

Number of views

33 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323-9.
Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis. 1993;167:1247-51.
Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a retrospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-17.
Bassetti M, Right E, Costa A, Fasce R, Molinari MP, Rosso R, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infectious Dis. 2006;6:21.
Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 2009;37:1612-8.
Kett DH, Azoulay E, Echeverria PM, Vincent JL, Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011;39:665-70.
Tabah A, Koulenti D, Laupland K, Misset B, Valles J, Bruzzi de Carvalho F, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med. 2012;38:1930-45.
Arnold HM, Micek ST, Shorr AF, Zilberberg MD, Labelle AJ, Kothari S, et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy. 2010;30:361-8.
Bassetti M, Trecarichi EM, Righi E, Sanguinetti M, Bisio F, Posteraro B, et al. Incidence, risk factors, and predictors of outcome of candidemia: survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis. 2007;58:325-31.
Bouza E, Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents. 2008;32:S87-91.
Picazo JJ, Gonzalez-Romo F, Candel FJ. Candidemia in the critically ill patient. Int J Antimicrob Agents. 2008;32:S83-5.
Falagas ME, Apostolou KE, Papas VD. Attributable mortality of candidemia: A systematic review of matched cohort and case control studies. Eur J Clin Microbiol Infect Dis. 2006;25:419-25.
Gudlaugsson O, Gillespie S, Lee K. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172-7.
Nolla-Salas J, Sitges-Serra A, Leon-Gil C, Martinez-Gonzalez J, Leon-Regidor MA, Ibanez-Lucia P, et al. Candidemia in nonneutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med. 1997;23:23-30.
Voss A, le Noble JL, Verduyn Lunel FM, Foudraine NA, Meis JF. Candidemia in intensive care unit patients: risk factors for mortality. Infection. 1997;25:8-11.
Lundberg JS, Perl TM, Wiblin T, Costigan MD, Dawson J, Nettleman MD, et al. Septic shock: an analysis of outcomes for patients with onset on hospital wards versus intensive care units. Crit Care Med. 1998;26:1020-4.
Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med. 1988;148:2642-5.
Bassetti M, Righi E, Ansaldi F, Merelli M, Cecilia T, De Pascale G, et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med. 2014;40:839-45.
Marriot D, Playford EG, Chen S, Slavin M, Nguyen Q, Ellis D, et al. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Critical Care. 2009;13:R115.
Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957-63.
Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707-10.
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-29.
Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med. 2008;36:2967-72.
Holley A, Dulhunty J, Blot S, Lipman J, Lobo S, Dancer C, et al. Temporal trends, risk factors and outcomes in albicans e non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. Int J Antimicrob Agents. 2009;33:554. e1-554.e7.
González de Molina FJ, León C, Ruiz-Santana S, Saavedra P, the CAVA I Study Group. Assessment of candidemia-attributable mortality in critically ill patients using propensity score matching analysis. Crit Care. 2012;16:R105.
Colombo AL, Guimarães T, Sukienik T, Pasqualotto AC, Andreotti R, Queiroz-Telles F, et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med. 2014;40:1489-98.
Blot S, Vandewoude KH, Hoste EA, Colardyn FA. Effects of Nosocomial Candidemia on Outcomes of Critically Ill Patients. Am J Med. 2002;113:480-5.
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589-96.
Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640-5.
Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25-31.
Patel GP, Simon D, Scheetz M, Crank CW, Lodise T, Patel N. The effect of time to antifungal therapy on mortality in Candidemia associated septic shock. Am J Ther. 2009;16:508-11.
Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother. 2007;60:613-8.
Klevay MJ, Ernst EJ, Hollanbaugh JL, Miller JG, Pfaller MA, Diekema DJ. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis. 2008;60:273-7.
Arendrup MC, Sulim S, Holm A, Nielsen L, Nielsen SD, Knudsen JD, et al. Diagnostic issues, clinical characteristics and outcomes for patients with fungemia. J Clin Microbiol. 2011;49:3300-8.
Kludze-Forson M, Eschenauer GA, Kubin CJ, Della-Latta P, Lam SW. The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection. Med Mycol. 2010;48:436-9.
Grim SA, Berger K, Teng C, Gupta S, Layden JE, Janda WM, et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother. 2012;67:707-14.
Charles PE, Doise JM, Quenot JP, Aube H, Dalle F, Chavanet P, et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med. 2003;29:2162-9.
Puig-Asensio M, Padilla B, Garnacho-Montero J, Zaragoza O, Aguado JM, Zaragoza R, et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect. 2015;21:491-500.
Pratikaki M, Platsouka E, Sotiropoulou C, Douka E, Paramythiotou E, Kaltsas P, et al. Epidemiology, risk factors for and outcome of candidaemia among non-neutropenic patients in a Greek intensive care unit. Mycoses. 2011;54:154-61.
Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, Ruiz Pérez de Pipaón M, Hernández-Caballero C, Lepe-Jiménez JÁ. Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections. J Antimicrob Chemother. 2013;68:206-13.
Guimarães T, Nucci M, Mendonça JS, Martinez R, Brito LR, Silva N, et al. Epidemiology and predictors of a poor outcome in elderly patients with candidemia. Intern J Infect Dis. 2012;16:e442-7.
Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, et al. Epidemiology and predictors of mortality in cases of Candida Bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. 2005;43:1829-35.